<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022163</url>
  </required_header>
  <id_info>
    <org_study_id>CP-H7VLP-006</org_study_id>
    <nct_id>NCT02022163</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.</brief_title>
  <official_title>Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicago</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Sciences Centre, Winnipeg, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I trial conducted in a single centre, observer-blind, randomized, dose-ranging,&#xD;
      placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of 2&#xD;
      intramuscular injections of plant-based H7 VLP Influenza Vaccine administered to healthy&#xD;
      adults, 18-60 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a dose-ranging in one hundred (100) subjects who will be&#xD;
      randomized in parallel to a 1:1:1:1:1 ratio in five (5) groups of 20 subjects to receive one&#xD;
      intramuscular injection at Days 0 and 21 of either a low, medium or high dose of H7 VLP&#xD;
      vaccine mixed with Alhydrogel® 0.4% (0.5 mg Aluminum per dose) or a high dose of H7 VLP alone&#xD;
      or the placebo preparation (100 millimolar (mM) phosphate buffer + 150 mM sodium chloride&#xD;
      (NaCl) + 0.01% Tween 80). Twenty-one (21) days after each immunization, key safety and&#xD;
      immunogenicity data will be collected and analysed. All subjects will be followed for safety&#xD;
      until Day 228.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>21 days after each injection and 6-month follow-up period</time_frame>
    <description>Safety will be assessed by the rate, severity and relationship to vaccination of solicited and unsolicited adverse events post-vaccinations. A 6-month follow-up period will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>21 days after each injection</time_frame>
    <description>Geometric mean titers (GMTs) of hemagglutination inhibition (HI antibody on Days 0, 21 and 42 to measure Geometric mean fold rise (GMFR) and seroconversion rates).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity 2</measure>
    <time_frame>21 days after injection and 6-month follow up</time_frame>
    <description>Geometric mean titers (GMTs) of hemagglutination inhibition (HI antibody on Days 0, 21 and 42 to measure seroprotection rates). Follow-up serology samples for GMTs will be taken at Day 228.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity 3</measure>
    <time_frame>21 days after each injection and 6 months follow up</time_frame>
    <description>Geometric mean titers (GMTs) of hemagglutination inhibition against heterologous influenza strains for cross-reactivity assessment. HI antibody on Days 0, 21 and 42 to measure seroconversion rates, GMFR and seroprotection rates. Follow-up serology samples for GMTs will be taken at Day 228.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Virus Diseases</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Low dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Med dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of H7 VLP vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 doses given 21 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose of H7 VLP vaccine + Alhydrogel</intervention_name>
    <description>Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
    <arm_group_label>Low dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Med dose of H7 VLP vaccine + Alhydrogel</intervention_name>
    <description>Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
    <arm_group_label>Med dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose of H7 VLP vaccine + Alhydrogel</intervention_name>
    <description>High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart</description>
    <arm_group_label>High dose of H7 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose of H7 VLP vaccine</intervention_name>
    <description>High dose of H7 VLP vaccine, 2 doses given 21 days apart</description>
    <arm_group_label>High dose of H7 VLP vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 doses given 21 days apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults, 18 to 60 years of age, inclusive&#xD;
&#xD;
          -  Healthy as judged by the Investigator or designee and determined by medical history,&#xD;
             complete general history/symptom-directed physical examination, vital signs, screening&#xD;
             laboratories, and medical history conducted no more than 30 days prior to study&#xD;
             vaccine administration&#xD;
&#xD;
          -  BMI of ≥18 and ≤32&#xD;
&#xD;
          -  Comprehension of the study requirements, expressed availability for the required study&#xD;
             period, and ability to attend scheduled visits&#xD;
&#xD;
          -  Accessible by phone on a consistent basis&#xD;
&#xD;
          -  Give his/her consent to participate in this study (by signing the ICF). In the opinion&#xD;
             of the Investigator, competence and willingness to provide written, informed consent&#xD;
             for participation after reading the informed consent form. The subject must have&#xD;
             adequate opportunity to discuss the study with an Investigator or qualified designee&#xD;
&#xD;
          -  If female, have a negative pregnancy test result prior to first immunization&#xD;
&#xD;
          -  Female of childbearing potential (except subjects in a monogamous same sex&#xD;
             relationship), must use an effective birth control for the 28 days prior to&#xD;
             immunization and must agree to continue employing adequate birth control measures from&#xD;
             Day 0 (first immunization) until at least 60 days post-second immunization and must&#xD;
             have no plan to become pregnant from Day 0 (first immunization) until at least 60 days&#xD;
             post-second immunization. Highly effective birth control includes hormonal&#xD;
             contraceptives (e.g., injectable, topical [patch], estrogenic vaginal ring, etc.),&#xD;
             intra-uterine device (IUD), abstinence (confirmed by Investigator), or male condom&#xD;
             plus spermicide. Abstinent subjects should be asked what method(s) they would use,&#xD;
             should their circumstances change, and subjects without a well-defined plan should be&#xD;
             excluded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of significant acute or chronic, uncontrolled medical or neuropsychiatric&#xD;
             illness. &quot;Uncontrolled&quot; is defined as&#xD;
&#xD;
          -  Requiring a new medical or surgical treatment within one month prior to study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Requiring a change in medication dosage in one month prior to study vaccine&#xD;
             administration due to uncontrolled symptoms or drug toxicity (elective dosage&#xD;
             adjustments in stable subjects are acceptable)&#xD;
&#xD;
          -  Hospitalization or an event fulfilling the definition of a serious adverse event&#xD;
             within one month prior to study vaccine administration&#xD;
&#xD;
          -  Any medical or neuropsychiatric condition or any history of excessive alcohol use or&#xD;
             drug abuse which, in the Investigator's opinion, would render the subject incompetent&#xD;
             to provide informed consent or unable to provide valid safety observations and&#xD;
             reporting&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive condition or immunodeficiency including&#xD;
             history of human immunodeficiency virus (HIV) infection, Hepatitis B or C, or the&#xD;
             presence of lymphoproliferative disease&#xD;
&#xD;
          -  Presence of any febrile illness, oral temperature of &gt;38.0˚C within 24 hours prior to&#xD;
             immunization. Such subjects may be re-evaluated for enrolment after resolution of&#xD;
             illness&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Administration of any vaccine (including any other influenza vaccine) within 30 days&#xD;
             prior to study enrolment or planned administration within the period from the&#xD;
             vaccination up to blood sampling at Day 42 or within 30 days prior to blood sampling&#xD;
             at Day 228. Immunization on an emergency basis of a tetanus and diphtheria toxoids&#xD;
             adsorbed for adult use (Td) will be allowed provided the vaccine is not administered&#xD;
             within two weeks prior to study vaccine administration. Receipt of any other emergency&#xD;
             immunizations (e.g., rabies) will result in a case-by-case review by the medical&#xD;
             monitor of continued participation&#xD;
&#xD;
          -  Administration of any adjuvanted or investigational influenza vaccine other than a&#xD;
             'simple' seasonal Trivalent Inactivated Vaccine (TIV) or Quadrivalent Inactivated&#xD;
             Vaccine (QIV) within 1 year prior to study enrolment or planned administration prior&#xD;
             to the end of this trial (Day 228)&#xD;
&#xD;
          -  Use of any investigational or non-registered product within 30 days prior to study&#xD;
             enrolment or planned use during the study period. Subjects may not participate in any&#xD;
             other investigational or marketed drug study while participating in this study&#xD;
&#xD;
          -  Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone per&#xD;
             day, or equivalent for more than 7 consecutive days or for 10 or more days in total,&#xD;
             within one month of study vaccine administration, any other cytotoxic or&#xD;
             immunosuppressant drug, or any globulin preparation within 3 months of vaccination.&#xD;
             Low doses of nasal or inhaled glucocorticoids are generally allowed&#xD;
&#xD;
          -  Use of high dose inhaled steroids or oral and parenteral high dose steroid&#xD;
             medications. Nasal steroids are allowed&#xD;
&#xD;
          -  Any significant disorder of coagulation or treatment with warfarin derivatives or&#xD;
             heparin. Persons receiving prophylactic anti-platelet medications, e.g., low-dose&#xD;
             aspirin [≤ 325 mg/day (1 regular adult aspirin) or ≤ 81 mg/day (1 baby aspirin)], and&#xD;
             without a clinically apparent bleeding tendency are eligible&#xD;
&#xD;
          -  History of previous H7N9 vaccination or a history of exposure to H7N9 virus. Any&#xD;
             subject that was enrolled on previous H7N9 studies (except the ones that received&#xD;
             placebo) would not be eligible&#xD;
&#xD;
          -  Are at high risk of contracting H7N9 influenza infection (e.g. poultry workers)&#xD;
&#xD;
          -  History of allergy to any of the constituents of the H7 VLP (H7N9) study vaccine,&#xD;
             Alhydrogel® (aluminum hydroxide), or to the phosphate-buffered saline (PBS) (used as&#xD;
             placebo)&#xD;
&#xD;
          -  History of severe allergic reactions (including anaphylaxis) to any food, medication&#xD;
             or bee sting or previous severe asthma.&#xD;
&#xD;
          -  History of tobacco allergy&#xD;
&#xD;
          -  Continuous use of anti-histamines in the last 4 weeks prior to first immunization or&#xD;
             use of anti-histamines 48 hours prior to each study immunization&#xD;
&#xD;
          -  Have a rash, dermatological condition, tattoos, or muscle mass at injection site which&#xD;
             may interfere with injection site reaction rating&#xD;
&#xD;
          -  Have received a blood transfusion within 90 days prior to study vaccination&#xD;
&#xD;
          -  If female, positive pregnancy test results at screening, and prior to immunizations on&#xD;
             Day 0 and Day 21&#xD;
&#xD;
          -  Female subjects who are lactating&#xD;
&#xD;
          -  Any vital sign abnormalities: systolic blood pressure, diastolic blood pressure,&#xD;
             resting heart rate not well controlled or according to the Investigator's opinion&#xD;
&#xD;
          -  Cancer or treatment for cancer within 3 years of study vaccine administration. Persons&#xD;
             with a history of cancer who are disease-free without treatment for 3 years or more&#xD;
             are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin&#xD;
             are eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Simonsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Science Centre for Human and Animal Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canadian Science Centre for Human and Animal Health</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Human</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Aluminum Hydroxide</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Immunogenic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

